These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20827391)

  • 1. Ferroportin and erythroid cells: an update.
    Cianetti L; Gabbianelli M; Sposi NM
    Adv Hematol; 2010; 2010():. PubMed ID: 20827391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.
    Gardenghi S; Marongiu MF; Ramos P; Guy E; Breda L; Chadburn A; Liu Y; Amariglio N; Rechavi G; Rachmilewitz EA; Breuer W; Cabantchik ZI; Wrighting DM; Andrews NC; de Sousa M; Giardina PJ; Grady RW; Rivella S
    Blood; 2007 Jun; 109(11):5027-35. PubMed ID: 17299088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
    Nyffenegger N; Flace A; Doucerain C; Dürrenberger F; Manolova V
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron dysregulation in beta-thalassemia.
    Leecharoenkiat K; Lithanatudom P; Sornjai W; Smith DR
    Asian Pac J Trop Med; 2016 Nov; 9(11):1035-1043. PubMed ID: 27890361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
    Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F
    J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.
    Gardenghi S; Grady RW; Rivella S
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1089-107. PubMed ID: 21075282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ineffective erythropoiesis and thalassemias.
    Rivella S
    Curr Opin Hematol; 2009 May; 16(3):187-94. PubMed ID: 19318943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulation of ferroportin gene expression in β(0)-thalassemia/Hb E disease.
    Sornjai W; Jaratsittisin J; Khungwanmaythawee K; Svasti S; Fucharoen S; Lithanatudom P; Smith DR
    Ann Hematol; 2016 Feb; 95(3):387-96. PubMed ID: 26666535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Therapeutic Advances in β-Thalassemia.
    Makis A; Voskaridou E; Papassotiriou I; Hatzimichael E
    Biology (Basel); 2021 Jun; 10(6):. PubMed ID: 34207028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models.
    Ramos P; Melchiori L; Gardenghi S; Van-Roijen N; Grady RW; Ginzburg Y; Rivella S
    Ann N Y Acad Sci; 2010 Aug; 1202():24-30. PubMed ID: 20712768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
    Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
    Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ineffective erythropoiesis in beta-thalassemia major is due to apoptosis at the polychromatophilic normoblast stage.
    Mathias LA; Fisher TC; Zeng L; Meiselman HJ; Weinberg KI; Hiti AL; Malik P
    Exp Hematol; 2000 Dec; 28(12):1343-53. PubMed ID: 11146156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What can we learn from ineffective erythropoiesis in thalassemia?
    Oikonomidou PR; Rivella S
    Blood Rev; 2018 Mar; 32(2):130-143. PubMed ID: 29054350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research progress of iron metabolism in phenotype modification of β-thalassemia].
    Chen D; Sun X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Jan; 38(1):27-31. PubMed ID: 33423253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic targets in transfusion-dependent and -independent thalassemia.
    Cappellini MD; Motta I
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia.
    Huang Y; Lei Y; Liu R; Liu J; Yang G; Xiang Z; Liang Y; Lai Y
    Int J Med Sci; 2019; 16(2):302-310. PubMed ID: 30745811
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.
    Gardenghi S; Ramos P; Marongiu MF; Melchiori L; Breda L; Guy E; Muirhead K; Rao N; Roy CN; Andrews NC; Nemeth E; Follenzi A; An X; Mohandas N; Ginzburg Y; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S
    J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk between Iron Metabolism and Erythropoiesis.
    Li H; Ginzburg YZ
    Adv Hematol; 2010; 2010():605435. PubMed ID: 20631898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth differentiation factor 15 in erythroid health and disease.
    Tanno T; Noel P; Miller JL
    Curr Opin Hematol; 2010 May; 17(3):184-90. PubMed ID: 20182355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepcidin-ferroportin axis in health and disease.
    Ginzburg YZ
    Vitam Horm; 2019; 110():17-45. PubMed ID: 30798811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.